

TITLE PAGE

Early Diagnosis of Cerebral Palsy in Preterm Infants with MRI, General Movements and Neurological Exam

Shipra Jain, MD,^{1,2,3} Karen Harpster, OTR/L, PhD,^{3,4,5} Stephanie Merhar, MD, MS,^{1,2,3} Beth Kline-Fath,^{3,6,7} Mekibib Altaye,^{3,8} Venkata Sita Priyanka Illapani^{1,3} Colleen Peyton, DPT,⁹ Nehal A. Parikh, DO, MS.^{1,2,3} for the Cincinnati Infant Neurodevelopment Early Prediction Study (CINEPS) Investigators

Affiliations:

¹The Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

²University of Cincinnati College of Medicine, Cincinnati, Ohio, United States

³Neurodevelopmental Disorders Prevention Center, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

⁴Division of Occupational Therapy and Physical Therapy, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

⁵Department of Rehabilitation, Exercise, and Nutrition Sciences, College of Allied Health Sciences, University of Cincinnati, Cincinnati, Ohio

⁶Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

⁷Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, Ohio

⁸Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

⁹Department of Physical Therapy and Human Movement Sciences and Department of Pediatrics, Northwestern University, Chicago, Illinois, USA

Conflict of Interest: None of the authors have any conflicts of interest to disclose. The funders played no role in the design, analysis, or presentation of the findings.

Funding Source: Supported by National Institutes of Health grants R01-NS094200 and R01-NS096037 from the National Institute of Neurological Disorders and Stroke (NINDS) and R01 EB029944-01 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) to Dr. Nehal Parikh.

Data Sharing Statement: All deidentified participant data can be requested from the corresponding author upon reasonable request.

Paper Presentation Information: This paper was presented at the Pediatric Academic Societies international meeting on April 30, 2023, in Washington, D.C. USA.

Corresponding Author: Nehal A. Parikh, DO, MS, Professor of Pediatrics, Cincinnati Children's Hospital Medical Center, 3333 Burnett Avenue, Cincinnati, Ohio, 45229, United States. Email: Nehal.Parikh@cchmc.org

Manuscript word count: 2999

Abstract word count: 343

Abstract

Background: The increasing clinical use of combining structural MRI (sMRI) with General Movements Assessment (GMA) or Hammersmith Infant Neurological Exam (HINE) before five months corrected age (CA) for early diagnosis of cerebral palsy (CP) lacks sufficient prognostic data for children with CP, especially those with Gross Motor Function Classification System (GMFCS) I.

Objective: Evaluate the predictive value of sMRI, GMA, and HINE individually and in combination for early CP diagnosis and assess accuracy across varying GMFCS levels in a regional cohort of preterm infants.

Methods: We performed sMRI between 39-44 weeks postmenstrual age and GMA and HINE between 12-18 weeks CA in 395 preterm infants born at ≤ 32 weeks' gestation across five NICUs in Greater Cincinnati. Brain abnormalities on sMRI included white matter injuries, cortical and deep gray matter lesions, or extensive cerebellar hemorrhage. Absent fidgety movements constituted abnormal GMA; abnormal HINEs were scores < 56 . The primary outcome was CP diagnosis at 22-26 months CA, classified by the GMFCS. We calculated sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratios for individual tests and combinations.

Results: Of 338 (86%) infants with complete follow-up, 48 (14.2%) showed sMRI abnormalities, 15 (4.6%) had abnormal GMA, and 69 (20.9%) had abnormal HINE. Thirty-nine children (11.5%) developed CP at age 2, of which 28 had GMFCS level I and 11 had GMFCS \geq II. The combination of sMRI and GMA achieved 100% specificity but only 22% sensitivity while the combination of abnormal sMRI and HINE demonstrated sensitivity of 32% and specificity of 98% for prediction of CP. Individual or combined tests showed far higher sensitivity (78-100%) for predicting CP in children with GMFCS levels II-V.

Conclusions: The combination of sMRI with GMA or HINE demonstrated high specificity but low sensitivity for early CP diagnosis in a regional cohort of preterm infants. This approach appears effective for early detection of CP levels II-V but not for level I cases, the most prevalent type, underscoring the need for continued developmental follow-up for all very preterm infants and need for more sensitive diagnostic tools for early detection of CP.

Key Words: Cerebral palsy, preterm infants, early diagnosis, structural MRI, General Movements Assessment, Hammersmith Infant Neurological Examination, neurodevelopment.

Key Points:

Questions: What is the individual and combined prognostic accuracy of sMRI, GMA, and HINE for early diagnosis of CP in preterm infants?

Findings: In our prospective, regional study of preterm infants born at ≤ 32 weeks' gestation, we found that combining brain abnormalities on sMRI with abnormal GMA achieved 100% specificity but 22% sensitivity for diagnosing CP. Individual or combined tests showed far higher sensitivity (78-100%) for predicting CP in children with GMFCS levels II-V. Both individual and combined tests were poor predictors of GMFCS level I CP, the most common type.

Meaning: While sMRI combined with GMA or HINE is effective for diagnosing CP with GMFCS levels II-V, this approach falls short for children with GMFCS level I.

Introduction:

Cerebral palsy (CP) affects 0.2-0.3% of live births in the United States,^{1,2} with risk increasing to 6-18% in preterm infants, particularly those born at ≤ 32 weeks gestational age (GA).^{1,3,4} CP is a movement and posture disorder caused by brain injury or abnormalities, with outcomes ranging from independent ambulation to complete dependence for all mobility.⁵ While a definitive cure for CP remains elusive, early intervention can curtail the progression of motor deficits, prevent secondary impairments, and enhance independence.⁶⁻⁸ The brain exhibits its highest levels of neuroplasticity during early life,⁹ underscoring the importance of early CP diagnosis and subsequent early intervention for improved prognosis.

Prognostic/diagnostic tools for detecting CP in infants below 5 months corrected age (CA) include structural magnetic resonance imaging (sMRI) at term-equivalent age (TEA), Prechtl's General Movements Assessment (GMA) during the fidgety period, and Hammersmith Infant Neurological Examination (HINE) at 3-4 months CA.¹⁰⁻¹² These tests individually lack sufficient predictive value for accurate CP diagnosis, and their combined effectiveness remains limited.¹³⁻¹⁵ A recent consensus recommended combining TEA-sMRI with GMA or HINE between 3-5 months CA for early diagnosis in high-risk newborns.¹⁶ While a retrospective case-control study reported 98% sensitivity and 99% specificity when combining neuroimaging (ultrasound or sMRI), GMA, and HINE¹⁴, only one cohort study (N=130) in very preterm infants assessed the prognostic value of combining sMRI with GMA, yielding positive predictive value (PPV) of 35% (sensitivity 70%; specificity 82%), falling short of previously reported findings and recommendations.¹⁵

The above guideline stated prognostic values from prior systematic reviews that reported sensitivity between 86%-89% for sMRI and 98% for GMA in predicting CP.¹⁶ However, these results should be applied cautiously to preterm infants. Many studies in the review^{12,14,16-24} focused on high-risk infants with perinatal asphyxia and stroke, where CP prevalence is much higher (6.3%–52.4%), potentially introducing bias and increasing the tests' prognostic accuracy. A large sMRI study (N=480), not included in the review, demonstrated a much lower sMRI sensitivity of 48% and a PPV of 17% for CP prediction.²⁵ Likewise, external validation studies by advanced GMA-trained practitioners revealed lower GMA sensitivity (50%–56%).^{15,26} Furthermore, predictive accuracy across different Gross Motor Functional Classification Scale (GMFCS) levels of CP remains underexplored.

To address these gaps, we prospectively evaluated the prognostic value of combining TEA-sMRI with GMA or HINE at 3-4 months CA for early CP diagnosis and assessed the predictive accuracy of these tools individually and in combination for varying CP GMFCS levels in preterm infants.

Methodology:

Study Design and Participants: Our multisite, prospective Cincinnati Infant Neurodevelopment Early Prediction Study (CINEPS) included 395 infants born at ≤ 32 weeks GA across five level III/IV neonatal intensive care units in Greater Cincinnati between 09/2016 to 11/2019, excluding infants with known congenital or chromosomal anomalies affecting the central nervous system or those still hospitalized at 44 weeks postmenstrual age (PMA), except those at Cincinnati Children's Hospital Medical Center, the imaging site. The Institutional Review Board approved the study, and written parental/guardian consents were obtained.

Structural MRI (sMRI) acquisition and assessment: We acquired high-resolution 3 Tesla T2-weighted, 3D T1-weighted, and susceptibility weighted MRI sequences at 39-44 weeks PMA to detect brain abnormalities (Supplement 1).²⁷ One neuroradiologist (B.M.K.F.), blinded to clinical and outcome data, evaluated scans with high intra-rater reliability.²⁸ sMRI was considered abnormal if it showed white matter injuries (e.g., cystic periventricular leukomalacia), encephalomalacia, periventricular hemorrhagic infarctions, lesions in the cortex or basal ganglia/thalamus, or extensive cerebellar hemorrhage—predictive abnormalities for CP, as outlined by Novak et al.¹⁶

Neurodevelopmental outcome assessment:

General Movement Assessment (GMA): GMA categorizes spontaneous movements in alert, quiet, infants. Infants between 12-18 weeks CA were video recorded and scored by an advanced Prechtl-certified examiner (K.H.), masked to clinical history and sMRI findings.^{29,30} The same examiner assessed the intra-rater reliability by re-evaluating 30 randomly selected videos 6 months later. Infants with normal fidgety movements exhibited variable, complex, and multiplanar movements, while those with absent or sporadic (≤ 3 seconds) fidgety movements were classified as having abnormal GMA, predictive of motor dysfunction, particularly CP.³⁰ No cohort infants exhibited abnormal fidgety movements (exaggerated amplitude or speed).^{31,32} A General Movements Trust trainer (C.P.) provided secondary assessment for equivocal videos.

Hammersmith Infant Neurological Examination (HINE): HINE is a standardized neurologic examination for infants aged 2-24 months CA evaluating infants' posture, tone, cranial nerves, reflexes, and spontaneous and voluntary movements, scoring infants on a 0-78 scale.²⁴ Scores < 56 were considered abnormal.³³ One examiner (K.H.), masked to clinical history and MRI findings, performed HINEs on the same day as GMAs. The same examiner assessed the intra-rater reliability by retesting 15 randomly selected infants 2-4 weeks after their initial HINE.

Neurological examination to determine CP diagnosis: Certified examiners³⁴ performed the Amiel-Tison standardized neurological exam³⁵ at 22-26 months CA to assess motor function and diagnose CP using Neonatal Research Network criteria: (1) abnormalities in tone, deep tendon reflexes, coordination, and/or movement, except isolated hypotonia or toe walking without tight ankles; (2) delays in motor milestones with motor dysfunction and (3) possible aberrations in reflexes and postural reactions. Because this definition permits a diagnosis of level I CP for a child with isolated toe walking with tight ankles, we required at least one additional delay in milestones or tone abnormalities for CP diagnosis. We used the GMFCS to rate CP gross motor

functional ability on a scale of I to V.^{36,37} Our primary outcome was CP diagnosis at 22-26 months CA.

Statistical analysis: We compared baseline differences between infants with and without CP and those who returned for follow-up at 2 years CA vs. those who did not, using Student's t-test, Mann Whitney U, Chi-Squared, or Fisher's exact test as appropriate. Intra-rater reliability was assessed using kappa statistics for dichotomous variables and intraclass correlation coefficient (ICC) for continuous variables. Fisher's exact test examined the sensitivity, specificity, PPV, and negative predictive value (NPV) of the three tests individually and in combination for CP diagnosis at 22-26 months CA. To account for disease prevalence between centers, we calculated likelihood ratios (LR+ and LR-) for positive and negative tests. Logistic regression determined the odds ratio for CP for individual and combined tests. Predicted post-test probabilities were derived using the *margins* command for different GMFCS levels in children with CP for each test and their combinations. Analysis was performed using Stata 17.0, with two-sided P values <0.05 considered significant.

Results:

Of 395 enrolled infants, two withdrew, and one died before age 2. At 12-18 weeks CA, 381 (97%) returned for GMA and HINE testing, and 338 (86%) underwent neurological examinations for CP diagnosis at 22-26 months CA. The mean (SD) GA was 29.3 (2.5) weeks, and the mean birth weight (SD) was 1294 (449) grams. Table 1 represents the demographic characteristics of infants with and without CP. The demographic characteristics of infants who returned for the 2-year evaluation versus those who did not, differed in their GA (29 weeks, 3 days with follow-up versus 30 weeks, 0 days without follow-up, $p=0.02$) and race/ethnicity, $p=0.003$.

We performed sMRI at a mean PMA of 42.3 (SD 1.3) weeks; 48 of 338 infants (14.2%) showed brain injury/abnormalities. GMA was completed for 329 infants between 12-18 weeks CA, with 97% conducted within the optimal 12-16 weeks CA. Fifteen (4.6%) infants had absent fidgety movements. HINE scores, available for 331 infants, ranged from 30.5 to 73 (median 60, IQR 7.0), with abnormal scores (<56) in 69 (20.9%) infants. Intra-rater reliability for GMA was 96.7% (kappa 0.89). Intra-rater ICC for HINE was 0.79.

At 22-26 months CA, 39 (11.5%) children were diagnosed with CP: 28 (8.3%) with GMFCS level I, 6 (1.8%) with GMFCS levels II-III, and 5 (1.5%) with GMFCS levels IV-V.²⁴ Among these 39 children diagnosed with CP, sMRI was abnormal in 18 (46.2%), GMA was abnormal in 10 (27.0%; two with missing GMA), and HINE was abnormal in 22 (57.9%; one with missing HINE) (Table 2; Table 3). Among 299 children without CP, 30 had abnormalities on their sMRI, 5 on GMA, and 47 on their HINE (Table 2). Only 8 infants had abnormal sMRI and GMA, and 17 infants had abnormal sMRI and HINE (Table 2; Table 3).

Table 3 represents the association between CP diagnosis and abnormal sMRI, GMA, and HINE. Infants with abnormal GMA exhibited the highest odds of developing CP at age 2 as compared to those with sMRI brain abnormalities or abnormal HINE. Combining abnormal sMRI with abnormal GMA resulted in 100% CP specificity, while combining sMRI with abnormal HINE increased the odds of developing CP from 7.7 to 26.6 (Table 4).

Infants with level II-V CP at age 2 had significantly higher odds of abnormal sMRI, GMA, and HINE, individually and in combination (Table 4). However, only brain abnormalities on sMRI and abnormal HINE individually significantly predicted level I CP with an odds ratio of 2.7 (95% CI: 1.1, 6.5) and 3.2 (1.5, 7.2), respectively. Neither abnormal GMA nor the combination approaches were predictive of level I CP.

Table 5 illustrates the individual and combined prognostic accuracy of sMRI, GMA, and HINE in predicting CP at age 2. Tests performed well individually or in combination in identifying/ruling in CP but performed poorly in ruling out CP. Combining sMRI with GMA or HINE enhanced specificity but greatly reduced sensitivity (from 46% for sMRI alone to 22% when combined with GMA). For levels II-V CP, all tests individually and in combination were effective in ruling in the diagnosis, but sensitivity, while higher than for level I CP, remained suboptimal. The sMRI and GMA combination performed best with a PPV of 88% and NPV of 99% for predicting levels II-V CP but performed poorly at predicting level I CP (Table 5).

The individual post-test probabilities for varying levels of GMFCS in children with CP demonstrates considerable discrepancies in test accuracy for predicting level I from level II-V CP across various individual prognostic tests and their combinations (eTable 2). When test results are negative, the individual level probability of developing level I CP was like the cohort prevalence (i.e., pre-test probability) of level I CP (8.3%). Conversely, abnormal GMA results individually or when combined with abnormal sMRI, exhibited more than 80% probability for developing CP by age 2.

Discussion:

Our regional multisite prospective cohort study of infants born at ≤ 32 weeks' GA assessed the predictive value of combining TEA-sMRI with GMA and/or HINE at 3-4 months CA for early CP prediction. The combined tests showed high specificity but suboptimal sensitivity in predicting CP, particularly for level I CP, representing most infants with CP in our cohort. Our findings offer new insights to guide the growing clinical practice of using sMRI with GMA/HINE for early prediction/diagnosis of CP.

While the 98% specificity of GMA in our cohort aligns with previous research, the 27% sensitivity is notably lower than the $>95\%$ sensitivity reported in most studies.^{12,15-21,23,24,26,38-42} These studies, including systematic reviews and meta-analyses,^{12,43} focused on high-risk infants with severe neuropathology, like perinatal asphyxia and stroke, and consequently a higher CP prevalence (6.3-52.4%), which may bias and inflate the test's prognostic properties.³⁵ Precht et al. reported high sensitivity by studying only infants with abnormal cranial ultrasound, resulting in a high CP prevalence of 37.6%.³⁹ Cohort studies from unselected population-based samples, like ours, demonstrated much lower GMA sensitivity. A Swiss cohort study of very preterm infants (n=535) with a CP prevalence of 7% reported 56% sensitivity (95% CI: 38-72%).²⁶ Similarly, a Dutch study from six well-baby clinics (n=455) reported 67% sensitivity (95% CI: 13-98%) in predicting CP.⁴⁴

Other studies illustrating higher sensitivity in preterm infants (85-97%) often had smaller sample sizes (79-115)⁴⁰⁻⁴² or earlier outcome assessments.^{15,26,41,42} An early diagnosis of CP before two years of age may overlook cases of CP with lower GMFCS levels and inflate the frequency of children with higher GMFCS levels, potentially leading to an increased sensitivity of GMA.⁴⁵ Notably, our study also observed a higher sensitivity of GMA for predicting levels II-V CP (89%, Table 5).

Similarly, the 84% specificity of HINE in our study aligns with findings from previous studies; however, the 58% sensitivity was notably lower than prior investigations.^{24,46-49} Similar to GMA prognostic studies, most prior HINE studies^{14,24,46-48,50} examined high-risk infants exhibiting a higher prevalence of brain abnormalities and/or CP than generally observed in preterm infants.

While our study's 90% specificity for brain MRI abnormalities aligned with previous findings, the 46% sensitivity was markedly lower than those reported by Novak et al. (86% to 89%).¹⁶ However, their data were derived from a cross-sectional MRI study,⁵¹ which cannot determine prognostic test properties, and from a systemic review that found only one eligible cohort study of 61 preterm infants.¹⁷ Prospective longitudinal studies in preterm infants,^{10,52-54} demonstrated between 50-67% sensitivity for moderate to severe abnormality on MRI at TEA to predict CP. The two largest MRI studies in preterm infants (total N=956)^{23,53} yielded a sensitivity of 48% and 60% for CP prediction, mirroring our findings and suggesting the need for additional tests to accurately screen for early CP.

Our study showed low sensitivity and high specificity for the combined use of sMRI, GMA, and/or HINE, suggesting it may not be adequate for screening very premature infants. While both high sensitivity and specificity are ideal for a prognostic test, high sensitivity is particularly

crucial for effective screening.⁵⁵ Due to the low sensitivity observed in our sample, even infants with negative results from combined assessments may still benefit from continued close monitoring for signs and symptoms of CP until at least 2 years CA. The low sensitivity of sMRI, alone or combined, may be partly due to the exclusion of some brain abnormalities, such as intraventricular hemorrhage without ventriculomegaly, that are predictive of CP in some studies but not consistently. However, this approach may improve sensitivity but at the cost of reducing specificity.

Our findings align with a multicenter cohort study of very premature infants (N=535), where combining cranial ultrasound abnormalities with GMA yielded only 15% (95% CI: 6-31%) sensitivity for detecting CP.²⁶ Contrastingly, a retrospective case-control study reported 98% sensitivity and 99% specificity when combining neuroimaging, GMA, and HINE.¹⁴ Our results may differ due to study design. Case-control studies often involve artificially altered outcome prevalence (50% in 1:1 matching) rather than reflecting natural disease prevalence.⁵⁶ Morgan et al., reported a 33% CP prevalence with 1:2 matching,¹⁴ considerably higher than the reported prevalence in very preterm infants, likely inflating sensitivity and specificity estimates.

Similarly, a small cohort study reported higher sensitivity (70%) for the sMRI and GMA combination,¹⁵ but their CP assessment was at 18 months CA. Because children with GMFCS I may be harder to diagnose before age 2, earlier diagnosis likely inflates the proportion of infants with higher GMFCS levels. In our study, the combined sensitivity of sMRI plus GMA to predict CP GMFCS levels II-V was 78%, with specificity of 99.7%, underscoring the robustness of this combined approach in identifying higher GMFCS levels. Interestingly, 72% of children with CP in our sample were classified as GMFCS I (n=28), who are more likely to score within typical ranges on the HINE⁴⁷ and GMA,⁵⁷ leading to false-negative results when assessed with the standard battery of early CP detection tools. This high proportion of children with GMFCS I in our sample may explain the lower sensitivity of these traditional early detection methods. Our findings emphasize the need to enhance detection methods for children at GMFCS level I, as infants in this group (with higher functional levels) respond particularly well to early therapeutic interventions.⁵⁸

We demonstrated consistently high specificity for CP prediction, particularly when combining the assessment tools. When sMRI was combined with GMA, the specificity and PPV both reached 100%. This enables clinicians to confidently diagnose CP as early as 3-4 months CA when both tests are positive, rather than simply categorizing an infant as high-risk for CP. Early diagnosis can facilitate enrollment in CP prevention/treatment trials, prompt targeted and high-dose early intervention, streamline appropriate funding, and provide social support to their caregivers.

Our study highlights a notable difference in the sensitivity of GMA and HINE whether used alone (27% vs. 58%) and or incorporated with sMRI (22% vs. 32%). The additional difference in specificity suggests these tests provide distinct prognostic information and should not be used interchangeably. Our earlier research bolsters these findings, demonstrating that GMA and HINE independently relate to sMRI abnormalities and have limited correlation.²⁷ This may be attributed to the likelihood that GMA and HINE assess distinct brain regions, indicating the importance of their combined utilization in clinical assessment.²⁷

Our study's strengths include being the largest prospective cohort study of preterm infants investigating the collective ability of sMRI, GMA, and HINE in forecasting CP. We minimized selection bias through consecutive recruitment of all preterm births born at ≤ 32 weeks' GA in Greater Cincinnati. We performed sMRI at TEA and GMA between 12-18-weeks CA, the optimal time for test performance. HINE and GMA were conducted on the same day by one provider with high reliability, masked to clinical history and sMRI results. Similar rigor was applied to sMRI readings. However, some assessments involved multiple raters to confirm findings, and about one-third of outcome assessors at age 2 were not blinded to clinical history or prior test results, potentially inflating prognostic test properties, though this was not observed for test sensitivity. Additionally, 14% attrition may introduce bias, though baseline characteristics were similar between those who returned for follow-up and those who did not, except for GA. Lastly, we did not derive motor optimality scores from GMA videos, which may yield more accurate results than assessing only absent, sporadic, and abnormal fidgety movements.⁵⁹

Conclusion

Our prospective multisite cohort study found that combining sMRI and GMA exhibited high specificity for predicting CP, enabling confident early diagnosis of CP for abnormal test results. However, test sensitivity, particularly for children with CP GMFCS level I, remained suboptimal. Consequently, continued follow-up in high-risk clinics and/or early intervention programs is required for all very preterm infants until more sensitive tools, including quantitative MRI and machine learning prognostic models, are developed to improve early diagnosis and aggressive prevention/treatment of CP.

Acknowledgements

This research was supported by grants R01-NS094200 and R01-NS096037 from the National Institute of Neurological Disorders and Stroke (NINDS) and R01-HL164420 from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. We sincerely thank the Cincinnati Infant Neurodevelopment Early Prediction Study (CINEPS) Investigators; Principal Investigator: Nehal A. Parikh, DO, MS; Collaborators (in alphabetical order): Mekibib Altaye, PhD, Anita Arnsperger, RRT, Traci Beiersdorfer, RN BSN, Kaley Bridgewater, RT(MR) CNMT, Tanya Cahill, MD, Kim Cecil, PhD, Kent Dietrich, RT, Christen Distler, BSN RNC-NIC, Juanita Dudley, RN BSN, Brianne Georg, BS, Cathy Grisby, RN BSN CCRC, Lacey Haas, RT(MR) CNMT, Karen Harpster, PhD, OT/RL, Lili He, PhD, Scott K. Holland, PhD, V.S. Priyanka Illapani, MS, Kristin Kirker, CRC, Julia E. Kline, PhD, Beth M. Kline-Fath, MD, Hailong Li, PhD, Matt Lanier, RT(MR) RT(R), Stephanie L. Merhar, MD MS, Greg Muthig, BS, Brenda B. Poindexter, MD MS, David Russell, JD, Sara Stacey, BSN, Kari Tepe, BSN RNC-NIC, Leanne Tamm, PhD, Julia Thompson, RN BSN, Jean A. Tkach, PhD, Hui Wang, PhD, Hui Wang, PhD, Jinghua Wang, PhD, Brynne Williams, RT(MR) CNMT, Kelsey Wineland, RT(MR) CNMT, Sandra Wuertz, RN BSN CCRP

Table 1: Baseline maternal and infant characteristics of children with and without cerebral palsy (CP)

Baseline Characteristics*	Children with CP (N=39)	Children without CP (N=299)	P Value
Maternal characteristics			
Antenatal steroids	31 (79.5%)	279 (93.3%)	0.008
Antenatal magnesium	30 (76.9%)	256 (85.6%)	0.161
Histologic chorioamnionitis, moderate-severe [†]	8 (24.2%)	15.7 (15.7%)	0.218
Hypertensive disorders of pregnancy	18 (46.2%)	122 (40.8 %)	0.605
High-risk social status	19 (48.7%)	126 (42.1%)	0.493
Multiple gestation	9 (23.1%)	113 (37.8%)	0.078
Household annual income ^{¶¶}			
Less than \$10,000	8/35 (22.8%)	42/288 (14.6%)	0.081
Between \$10,000 - \$29,999	10/35 (28.6%)	60/288 (20.8%)	
Between \$30,000 - \$59,999	3/35 (8.6%)	53/288 (18.4%)	
Between \$60,000 - \$99,999	9/35 (25.7%)	55/288 (19.1%)	
More than \$100,000	4/35 (11.4%)	56/288 (19.4%)	
Prefer not to answer	1/35 (2.8%)	22/288 (7.6%)	
Maternal education [§]			
Less than high school diploma or GED	3/36 (8.3%)	16/276 (5.8%)	0.398
High school diploma or GED	8/36 (22.2%)	56/276 (20.3%)	
Some college	10/36 (27.8%)	77/276 (27.9%)	
College degree	9/36 (25.0%)	69/276 (25.0%)	
Some graduate school	3/36 (8.3%)	7/276 (2.5%)	
Graduate degree or higher	3/36 (8.3%)	51/276 (18.5%)	
Race/Ethnicity ^{##}			
White	26/39 (66.7%)	198/296 (67.0%)	0.980
Black	10/39 (25.6%)	68/296 (22.9%)	
Asian	0 /39 (0%)	7/296 (2.4%)	
Hispanic	1/39 (2.6%)	16/296 (5.4%)	
Other	2/39 (5.1%)	7/296 (2.4%)	
Neonatal characteristics			
Gestational age, weeks, mean (SD)	27.58 (2.71)	29.35 (2.40)	0.003
Birth weight, Z-score, mean (SD)	0.39 (1.22)	0.04 (0.91)	0.149
Sex, female	13 (33.3%)	149 (49.8%)	0.061
Severe IVH/PVL ^{**}	13 (33.3%)	17 (5.7%)	<.001
Sepsis	5 (12.8%)	33 (11.0%)	0.787
Necrotizing enterocolitis	4 (10.3%)	12 (4.0%)	0.099
Bronchopulmonary dysplasia, moderate-severe [€]	17 (43.5%)	51 (17.1%)	<.001
Retinopathy of prematurity, severe	5 (12.8%)	16 (5.4%)	0.080
Major surgery requiring general anesthesia	8 (20.5%)	31 (10.4%)	0.104
Brain abnormalities on sMRI [#]	18 (46.2%)	30 (10.0%)	
Extensive white matter hemorrhage	6 (15.4%)	7 (2.3%)	<.001
White matter cystic changes	5 (12.8%)	3 (1.0%)	
Porencephalic changes	5 (12.8%)	3 (1.0%)	
Deep gray matter hemorrhage	6 (15.4%)	0	
Deep gray matter non-hemorrhagic injury	2 (5.1%)	2 (0.7%)	
Posterior limb of internal capsule abnormality	3 (7.7%)	0	
Extensive cerebellar hemorrhage	9 (23.1%)	19 (6.4%)	

*All the values are n (%) unless otherwise specified.

[¶]Data imputed using K-nearest neighbor imputation for 42 cases

^{¶¶}Family income data missing for 11 mothers whose children did not develop CP and four whose children did develop CP

[§]Maternal education data missing for 23 mothers whose children did not develop CP and three whose children did develop CP

^{###}Race/ethnicity data missing for three mothers whose children did not develop CP

**Severe intraventricular hemorrhage (Papile grades III/IV) or periventricular leukomalacia on cranial ultrasound.

€Grade 2 or 3 bronchopulmonary dysplasia coded using Jenson EA, 2019 definition at 36 weeks postmenstrual age.

#Brain abnormalities on sMRI: cystic periventricular leukomalacia, encephalomalacia, and/or periventricular hemorrhagic infarctions, cortical and basal ganglia/thalamus lesions, and/or extensive cerebellar hemorrhage.¹⁶

Abbreviations: CP= cerebral palsy, IVH=intraventricular hemorrhage, PVL=periventricular leukomalacia, SD=standard deviation, sMRI=structural magnetic resonance imaging

Table 2. Frequency of abnormalities on individual and combination prognostic tests in children with and without cerebral palsy (CP)

Test(s)*	Children with CP (N=39)	Children without CP (N=299)	P Value
Abnormal sMRI	18/39 (46.2%)	30/299 (10.0%)	<0.001
Abnormal GMA	10/37 (27.0%)	5/292 (1.7%)	<0.001
Abnormal HINE	22/38 (57.9%)	47/293 (16.0%)	<0.001
HINE Score, median (range)	55 (30.5 - 71)	60 (38.5 – 73)	<0.001
Abnormal sMRI and GMA	8/37 (21.6%)	0/292 (0%)	<0.001
Abnormal sMRI and HINE	12/38 (31.6%)	5/293 (1.7%)	<0.001
Abnormal sMRI and GMA or HINE	12/38 (31.6%)	5/293 (1.7%)	<0.001
Bayley Motor score, median (range)	73 (46 – 112)	94 (55-130)	<0.001

*All values are n (%) unless otherwise noted

Abbreviations: CP= cerebral palsy, sMRI=structural magnetic resonance imaging, GMA=general movement assessment, HINE= Hammersmith Infant Neurological Examination

Table 3. Abnormality on structural MRI (sMRI), general movements assessment (GMA), and/or Hammersmith Infant Neurological Exam (HINE) for all 39 infants diagnosed with cerebral palsy at age 2 years corrected age and associated Gross Motor Functional Classification Scale (GMFCS) in the cohort.

sMRI Abnormality	GMA Abnormal	HINE Abnormal	HINE Score	CP at 2 Years	GMFCS Level
No	No	No	71	Yes	I
No	No	Yes	55	Yes	I
Yes	Yes	Yes	42	Yes	I
Yes	No	No	64	Yes	IV
No	No	No	63.5	Yes	I
Yes	No	No	64.5	Yes	I
No	Yes	Yes	52	Yes	III
No	No	No	57	Yes	I
Yes	Yes	Yes	51	Yes	III
No	No	No	61	Yes	I
No	No	Yes	30.5	Yes	I
No	No	No	56	Yes	I
Yes	No	No	64	Yes	I
No	Yes	Yes	55	Yes	I
Yes	No	No	63	Yes	I
No	No	Yes	41	Yes	I
Yes	No	Yes	51.5	Yes	I
Yes	Yes	Yes	30.5	Yes	V
No	No	No	61	Yes	I
Yes	No	Yes	36	Yes	III
No	No	Yes	55	Yes	I
Yes	Yes	Yes	52	Yes	III
Yes	Yes	Yes	37	Yes	IV
Yes	No	Yes	49.5	Yes	I
Yes	Yes	Yes	32	Yes	V
Yes	Yes	Yes	42.5	Yes	V
No	No	No	63	Yes	I
No	No	Yes	54.5	Yes	I
No	No	No	62.5	Yes	I
Yes	Missing	Missing	Missing	Yes	II
No	No	No	58	Yes	I
No	No	No	59.5	Yes	I
Yes	No	No	63	Yes	I
No	No	Yes	54	Yes	I
No	No	No	65	Yes	I
No	No	Yes	50	Yes	I
Yes	Yes	Yes	53.5	Yes	I
No	No	Yes	55	Yes	I
Yes	Missing	Yes	45	Yes	II
18/39 (46.2%)	10/37 (27.0%)	22/38 (57.9%)	55 (49.5-62.5)*	39/39 (100%)	N/A

*Median (IQR)

Table 4. Odds of abnormal structural MRI (sMRI), general movement assessment (GMA), and Hammersmith Infant Neurological Examination (HINE) and prediction of cerebral palsy (CP) at 2 years corrected age in preterm infants.

Outcomes	Odds Ratio	P value
Any CP		
sMRI	7.7 (3.7, 16.0)	<0.001
GMA	21.3 (6.8, 66.7)	<0.001
HINE	7.2 (3.5, 14.7)	<0.001
sMRI plus GMA*	N/A	N/A
sMRI plus HINE [†]	26.6 (8.7, 81.3)	<0.001
CP GMFCS levels II-V[#]		
sMRI	76.1 (9.5, 610.8)	<0.001
GMA	357.7 (39.3, 3259.8)	<0.001
HINE**	N/A	N/A
sMRI plus GMA	1116.5 (90.3, 13801.2)	<0.001
sMRI plus HINE [†]	352.1 (39.7, 3121.0)	<0.001
CP GMFCS level I[#]		
sMRI	2.7 (1.1, 6.5)	0.028
GMA	1.7 (0.4, 8.0)	0.498
HINE	3.2 (1.5, 7.2)	0.004
sMRI plus GMA	1.6 (0.18, 13.1)	0.685
sMRI plus HINE [†]	2.5 (0.7, 9.2)	0.175

*Predicts success perfectly due to 100% specificity

**Predicts success perfectly due to 100% sensitivity

[†]Results for sMRI and GMA OR sMRI and HINE were identical to this group

[#] GMFCS Level I is defined as an infant's ability to move in and out of sitting and floor sit with both hands free to manipulate objects. Infants crawl on hands and knees, pull to stand and take steps holding on to furniture. Infants walk 10 steps independently, with hands free, but with some gait abnormalities – includes toe walking, asymmetric walking, wide based gait with coordination or ataxic gait. Level II to V are characterized by increasing levels of limitations to walking and voluntary control of movement in other muscles.^{36,37}

Abbreviations: CP= cerebral palsy, sMRI=structural magnetic resonance imaging, GMA=general movement assessment, HINE= Hammersmith Infant Neurological Examination, GMFCS= Gross Motor Functional Classification Scale

Table 5: Prognostics accuracy of structural MRI (sMRI), general movement assessment (GMA), and Hammersmith Infant Neurological Examination (HINE) for prediction of cerebral palsy (CP) at 2 years corrected age in preterm infants.

Prognostic Models	Sensitivity	Specificity	PPV	NPV	LR+	LR-	AUC
Any CP							
sMRI	0.46	0.90	0.38	0.93	4.6	0.60	0.681
GMA	0.27	0.98	0.67	0.91	15.8	0.74	0.627
HINE	0.58	0.84	0.32	0.94	3.6	0.50	0.709
sMRI plus GMA	0.22	1.00	1.00	0.89	∞	0.78	N/A*
sMRI plus HINE	0.32	0.98	0.72	0.92	18.5	0.70	0.649
CP GMFCS levels II-V[#]							
sMRI	0.91	0.88	0.21	0.997	7.8	0.10	0.896
GMA	0.89	0.98	0.53	0.997	40.6	0.11	0.934
HINE	1.00	0.82	0.15	1.00	5.4	0	N/A**
sMRI plus GMA	0.78	0.997	0.88	0.99	248.9	0.22	0.887
sMRI plus HINE	0.90	0.98	0.53	0.997	36.1	0.10	0.938
CP GMFCS level I[#]							
sMRI	0.29	0.87	0.17	0.93	2.2	0.82	0.578
GMA	0.07	0.86	0.13	0.92	1.7	0.98	0.514
HINE	0.43	0.81	0.17	0.84	2.3	0.70	0.620
sMRI plus GMA	0.04	0.98	0.13	0.92	1.5	0.99	0.506
sMRI plus HINE	0.11	0.95	0.18	0.92	2.3	0.94	0.531

*Predicts success perfectly due to 100% specificity

**Predicts success perfectly due to 100% sensitivity

[#] GMFCS Level I is defined as an infant's ability to move in and out of sitting and floor sit with both hands free to manipulate objects. Infants crawl on hands and knees, pull to stand and take steps holding on to furniture. Infants walk 10 steps independently, with hands free, but with some gait abnormalities – includes toe walking, asymmetric walking, wide based gait with coordination or ataxic gait. Level II to V are characterized by increasing levels of limitations to walking and voluntary control of movement in other muscles.^{36,37}

Abbreviations: CP= cerebral palsy, sMRI=structural magnetic resonance imaging, GMA=general movement assessment, HINE= Hammersmith Infant Neurological Examination, GMFCS= Gross Motor Functional Classification Scale

References

1. Oskoui M, Coutinho F, Dykeman J, Jetté N, Pringsheim T. An update on the prevalence of cerebral palsy: A systematic review and meta-analysis. *Dev Med Child Neurol*. 2013;55(6). doi:10.1111/dmcn.12080
2. Durkin MS, Benedict RE, Christensen D, et al. Prevalence of Cerebral Palsy among 8-Year-Old Children in 2010 and Preliminary Evidence of Trends in Its Relationship to Low Birthweight. *Paediatr Perinat Epidemiol*. 2016;30(5). doi:10.1111/ppe.12299
3. Galea C, McIntyre S, Smithers-Sheedy H, et al. Cerebral palsy trends in Australia (1995–2009): a population-based observational study. *Dev Med Child Neurol*. 2019;61(2). doi:10.1111/dmcn.14011
4. Vohr BR, Wright LL, Poole WK, McDonald SA. Neurodevelopmental outcomes of extremely low birth weight infants <32 weeks' gestation between 1993 and 1998. *Pediatrics*. 2005;116(3). doi:10.1542/peds.2004-2247
5. Rosenbaum P. Chapter 20 - Gross motor development in children with cerebral palsy: what do we know, and how may that knowledge help? In: Bower E, ed *Finnie's Handling the Young Child with Cerebral Palsy at Home (Fourth Edition)*; Edinburgh: Butterworth-Heinemann. Published online 2009:269-281.
6. Hadders-Algra M. Early Diagnosis and Early Intervention in Cerebral Palsy. *Front Neurol*. 2014;5. doi:10.3389/fneur.2014.00185
7. Morgan C, Fetters L, Adde L, et al. Early Intervention for Children Aged 0 to 2 Years with or at High Risk of Cerebral Palsy: International Clinical Practice Guideline Based on Systematic Reviews. *JAMA Pediatr*. 2021;175(8). doi:10.1001/jamapediatrics.2021.0878
8. Damiano DL, Longo E. Early intervention evidence for infants with or at risk for cerebral palsy: an overview of systematic reviews. *Dev Med Child Neurol*. 2021;63(7). doi:10.1111/dmcn.14855
9. Power JD, Schlaggar BL. Neural plasticity across the lifespan. *Wiley Interdiscip Rev Dev Biol*. 2017;6(1). doi:10.1002/wdev.216
10. van't Hooft J, van der Lee JH, Opmeer BC, et al. Predicting developmental outcomes in premature infants by term equivalent MRI: Systematic review and meta-analysis. *Syst Rev*. 2015;4(1). doi:10.1186/s13643-015-0058-7
11. Romeo DM, Ricci D, Brogna C, Mercuri E. Use of the Hammersmith Infant Neurological Examination in infants with cerebral palsy: A critical review of the literature. *Dev Med Child Neurol*. 2016;58(3). doi:10.1111/dmcn.12876
12. Kwong A, Fitzgerald T, Doyle L, Cheong J, Spittle A. Spontaneous early infant movements that predict later cerebral palsy: A systematic review and meta-analysis. *Dev Med Child Neurol*. 2018;60.
13. Parikh NA. Are structural magnetic resonance imaging and general movements assessment sufficient for early, accurate diagnosis of cerebral palsy? *JAMA Pediatr*. 2018;172(2). doi:10.1001/jamapediatrics.2017.4812
14. Morgan C, Romeo DM, Chorna O, et al. The pooled diagnostic accuracy of neuroimaging, general movements, and neurological examination for diagnosing cerebral palsy early in high-risk infants: A case control study. *J Clin Med*. 2019;8(11). doi:10.3390/jcm8111879
15. Constantinou JC, Adamson-Macedo EN, Mirmiran M, Fleisher BE. Movement, imaging and neurobehavioral assessment as predictors of cerebral palsy in preterm infants. *Journal of Perinatology*. 2007;27(4). doi:10.1038/sj.jp.7211664

16. Novak I, Morgan C, Adde L, et al. Early, accurate diagnosis and early intervention in cerebral palsy: Advances in diagnosis and treatment. *JAMA Pediatr.* 2017;171(9). doi:10.1001/jamapediatrics.2017.1689
17. Bosanquet M, Copeland L, Ware R, Boyd R. A systematic review of tests to predict cerebral palsy in young children. *Dev Med Child Neurol.* 2013;55(5). doi:10.1111/dmcn.12140
18. Øberg GK, Jacobsen BK, Jørgensen L. Predictive value of general movement assessment for cerebral palsy in routine clinical practice. *Phys Ther.* 2015;95(11). doi:10.2522/ptj.20140429
19. Adde L, Rygg M, Lossius K, Øberg GK, Støen R. General movement assessment: Predicting cerebral palsy in clinical practise. *Early Hum Dev.* 2007;83(1). doi:10.1016/j.earlhumdev.2006.03.005
20. Ferrari F, Cioni G, Einspieler C, et al. Cramped synchronized general movements in preterm infants as an early marker for cerebral palsy. *Arch Pediatr Adolesc Med.* 2002;156(5). doi:10.1001/archpedi.156.5.460
21. Dimitrijević L, Bjelaković B, Čolović H, et al. Assessment of general movements and heart rate variability in prediction of neurodevelopmental outcome in preterm infants. *Early Hum Dev.* 2016;99. doi:10.1016/j.earlhumdev.2016.05.014
22. A. K, T. F, L. D, J. C, A. S. Spontaneous early infant movements that predict later cerebral palsy: A systematic review and meta-analysis. *Dev Med Child Neurol.* 2018;60.
23. Seme-Ciglencečki P. Predictive Value of Assessment of General Movements for Neurological Development of High-Risk Preterm Infants: Comparative Study. *Croat Med J.* 2003;44(6).
24. Maurizio Romeo DM, Guzzetta A, Scoto M, et al. Early neurologic assessment in preterm-infants: Integration of traditional neurologic examination and observation of general movements. *European Journal of Paediatric Neurology.* 2008;12(3). doi:10.1016/j.ejpn.2007.07.008
25. Hintz SR, Barnes PD, Bulas D, et al. Neuroimaging and neurodevelopmental outcome in extremely preterm infants. *Pediatrics.* 2015;135(1). doi:10.1542/peds.2014-0898
26. Datta AN, Furrer MA, Bernhardt I, et al. Fidgety movements in infants born very preterm: predictive value for cerebral palsy in a clinical multicentre setting. *Dev Med Child Neurol.* 2017;59(6). doi:10.1111/dmcn.13386
27. Harpster K, Merhar S, Priyanka Illapani VS, Peyton C, Kline-Fath B, Parikh NA. Associations Between Early Structural Magnetic Resonance Imaging, Hammersmith Infant Neurological Examination, and General Movements Assessment in Infants Born Very Preterm. *Journal of Pediatrics.* 2021;232. doi:10.1016/j.jpeds.2020.12.056
28. Tamm L, Patel M, Peugh J, Kline-Fath BM, Parikh NA. Early brain abnormalities in infants born very preterm predict under-reactive temperament. *Early Hum Dev.* 2020;144. doi:10.1016/j.earlhumdev.2020.104985
29. Einspieler C, Prechtl HFR, Ferrari F, Cioni G, Bos AF. The qualitative assessment of general movements in preterm, term and young infants - Review of the methodology. *Early Hum Dev.* 1997;50(1). doi:10.1016/S0378-3782(97)00092-3
30. Einspieler C, Prechtl HFR. Prechtl's assessment of general movements: A diagnostic tool for the functional assessment of the young nervous system. *Ment Retard Dev Disabil Res Rev.* 2005;11(1). doi:10.1002/mrdd.20051
31. Einspieler C, Yang H, Bartl-Pokorny KD, et al. Are sporadic fidgety movements as clinically relevant as is their absence? *Early Hum Dev.* 2015;91(4). doi:10.1016/j.earlhumdev.2015.02.003
32. Støen R, Boswell L, de Regnier RA, et al. The predictive accuracy of the general movement assessment for cerebral palsy: A prospective, observational study of high-risk infants in a clinical follow-up setting. *J Clin Med.* 2019;8(11). doi:10.3390/jcm8111790

33. Romeo DMM, Cioni M, Palermo F, Cilauro S, Romeo MG. Neurological assessment in infants discharged from a neonatal intensive care unit. *European Journal of Paediatric Neurology*. 2013;17(2). doi:10.1016/j.ejpn.2012.09.006
34. Newman JE, Bann CM, Vohr BR, Dusick AM, Higgins RD. Improving the neonatal research network annual certification for neurologic examination of the 18-22 month child. *Journal of Pediatrics*. 2012;161(6). doi:10.1016/j.jpeds.2012.05.048
35. Amiel-Tison C GJ. Neurological development from birth to six years: guide for examination and evaluation. *Baltimore: Johns Hopkins University Press Baltimore*. Published online 2001.
36. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. *Dev Med Child Neurol*. 1997;39(4). doi:10.1111/j.1469-8749.1997.tb07414.x
37. Palisano RJ, Hanna SE, Rosenbaum PL, et al. Validation of a model of gross motor function for children with cerebral palsy. *Phys Ther*. 2000;80(10). doi:10.1093/ptj/80.10.974
38. Morgan C, Crowle C, Goyen TA, et al. Sensitivity and specificity of General Movements Assessment for diagnostic accuracy of detecting cerebral palsy early in an Australian context. *J Paediatr Child Health*. 2016;52(1). doi:10.1111/jpc.12995
39. Prechti HFR, Einspieler C, Cioni G, Bos AF, Ferrari F, Sontheimer D. An early marker for neurological deficits after perinatal brain lesions. *Lancet*. 1997;349(9062). doi:10.1016/S0140-6736(96)10182-3
40. Spittle AJ, Spencer-Smith MM, Cheong JLY, et al. General movements in very preterm children and neurodevelopment at 2 and 4 years. *Pediatrics*. 2013;132(2). doi:10.1542/peds.2013-0177
41. Spittle AJ, Boyd RN, Inder TE, Doyle LW. Predicting motor development in very preterm infants at 12 months' corrected age: The role of qualitative magnetic resonance imaging and general movements assessments. *Pediatrics*. 2009;123(2). doi:10.1542/peds.2008-0590
42. Burger M, Louw QA. The predictive validity of general movements - A systematic review. *European Journal of Paediatric Neurology*. 2009;13(5). doi:10.1016/j.ejpn.2008.09.004
43. Groos D, Adde L, Aubert S, et al. Development and Validation of a Deep Learning Method to Predict Cerebral Palsy From Spontaneous Movements in Infants at High Risk. *JAMA Netw Open*. 2022;5(7):e2221325. doi:10.1001/jamanetworkopen.2022.21325
44. Bouwstra H, Dijk-Stigter GR, Grooten HMJ, et al. Predictive value of definitely abnormal general movements in the general population. *Dev Med Child Neurol*. 2010;52(5). doi:10.1111/j.1469-8749.2009.03529.x
45. Peralta-Carcelen M, Moses M, Adams-Chapman I, et al. Stability of neuromotor outcomes at 18 and 30 months of age after extremely low birth weight status. *Pediatrics*. 2009;123(5):e887-95. doi:10.1542/peds.2008-0135
46. Romeo DMM, Cioni M, Scoto M, Pizzardi A, Romeo MG, Guzzetta A. Prognostic value of a scorable neurological examination from 3 to 12 months post-term age in very preterm infants: A longitudinal study. *Early Hum Dev*. 2009;85(6). doi:10.1016/j.earlhumdev.2009.01.004
47. Romeo DMM, Cioni M, Scoto M, Mazzone L, Palermo F, Romeo MG. Neuromotor development in infants with cerebral palsy investigated by the Hammersmith Infant Neurological Examination during the first year of age. *European Journal of Paediatric Neurology*. 2008;12(1). doi:10.1016/j.ejpn.2007.05.006
48. Romeo DM, Cowan FM, Haataja L, et al. Hammersmith Infant Neurological Examination for infants born preterm: predicting outcomes other than cerebral palsy. *Dev Med Child Neurol*. 2021;63(8). doi:10.1111/dmcn.14768

49. Pietruszewski L, Batterson N, Nelin M, Lewandowski D, Burkhardt S, Maitre N. Combining the test of motor performance with the Hammersmith infant neurological examination as a successful secondary approach to early detection of cerebral palsy. *Dev Med Child Neurol*. 2019;61.
50. Pietruszewski L, Moore-Clingenpeel M, Moellering GCJ, Lewandowski D, Batterson N, Maitre NL. Predictive value of the test of infant motor performance and the Hammersmith infant neurological examination for cerebral palsy in infants. *Early Hum Dev*. 2022;174. doi:10.1016/j.earlhumdev.2022.105665
51. Ashwal S, Russman BS, Blasco PA, et al. Practice Parameter: Diagnostic assessment of the child with cerebral palsy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. 2004;62(6). doi:10.1212/01.WNL.0000117981.35364.1B
52. Woodward LJ, Anderson PJ, Austin NC, Howard K, Inder TE. Neonatal MRI to Predict Neurodevelopmental Outcomes in Preterm Infants. *New England Journal of Medicine*. 2006;355(7). doi:10.1056/nejmoa053792
53. Edwards AD, Redshaw ME, Kennea N, et al. Effect of MRI on preterm infants and their families: a randomised trial with nested diagnostic and economic evaluation. *Arch Dis Child Fetal Neonatal Ed*. 2018;103(1). doi:10.1136/archdischild-2017-313102
54. Marcroft C, Dulson P, Dixon J, Embleton N, Basu AP. The predictive ability of the Lacey Assessment of Preterm Infants (LAPI), Cranial Ultrasound (cUS) and General Movements Assessment (GMA) for Cerebral Palsy (CP): A prospective, clinical, single center observational study. *Early Hum Dev*. 2022;170. doi:10.1016/j.earlhumdev.2022.105589
55. Trevethan R. Sensitivity, Specificity, and Predictive Values: Foundations, Pliabilities, and Pitfalls in Research and Practice. *Front Public Health*. 2017;5. doi:10.3389/fpubh.2017.00307
56. Mathes T, Pieper D. An algorithm for the classification of study designs to assess diagnostic, prognostic and predictive test accuracy in systematic reviews. *Syst Rev*. 2019;8(1). doi:10.1186/s13643-019-1131-4
57. Einspieler C, Bos AF, Kriebler-Tomantschger M, et al. Cerebral palsy: Early markers of clinical phenotype and functional outcome. *J Clin Med*. 2019;8(10). doi:10.3390/jcm8101616
58. Nordstrand L, Holmefur M, Kits A, Eliasson AC. Improvements in bimanual hand function after baby-CIMT in two-year old children with unilateral cerebral palsy: A retrospective study. *Res Dev Disabil*. 2015;41-42. doi:10.1016/j.ridd.2015.05.003
59. Crowle C, Jackman M, Morgan C. The General Movements Motor Optimality Score in High-Risk Infants: A Systematic Scoping Review. *Pediatric Physical Therapy*. 2023;35(1). doi:10.1097/PEP.0000000000000969